Jounce Therapeutics, Inc. (JNCE) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $11.45, down from yesterday’s close by -35.20%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.Fundamental Analysis
Jounce Therapeutics, Inc. (JNCE) currently trades with a market capitalization of $367.77 Million. That value represents a market adjusting for revenues that have been falling by -44.82 % on a quarterly year/year basis as of the company’s last quarterly report.
You can get a sense of how sustainable that is by a levered free cash flow of -$102.68 Million over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of -$0.31 on a per share basis this quarter. Perhaps, that suggests something about why 0.29% of the outstanding share supply is held by institutional investors.
As most professionals know, technical analysis can offer critical insights into what smart money and insiders think about a stock’s prospects going forward. Looking at the stock’s movement on the chart, Jounce Therapeutics, Inc. recorded a 52-week high of $29.25. It is now trading 17.8% off that level. The stock is trading $21.26 its 50-day moving average by 9.81%. The stock carved out a 52-week low down at $11.05.
In recent action, Jounce Therapeutics, Inc. (JNCE) has made a move of -42.11% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 15.08, and it’s gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 15.85% with $27.43 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of JNCE.